ReviewCurrent research in pharmacology and drug discovery2022
When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.
Review in Current research in pharmacology and drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.Journal of Crohn's & colitis · 2024Trial
- The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States.Therapeutic advances in gastroenterology · 2026Article
- Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis.Inflammatory bowel diseases · 2025Article
- Management of Patients With Refractory Ulcerative Proctitis.Gastroenterology & hepatology · 2025Article
- Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments.Infectious disorders drug targets · 2025Review
- Delphi consensus survey: the opinions of patients living with refractory ulcerative proctitis and the health care professionals who care for them.BMJ open gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases.
objectivesTo summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options.
results/Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.